XAIR

Beyond Air, Inc. [XAIR] Stock Forecast

Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
RSI : 000

XAIR Stock Summary

Top 10 Correlated Stocks

XAIR

In the News

XAIR Financial details

Company Rating
-
Market Cap
66.1M
Income
-66.7M
Revenue
689K
Book val./share
-
Cash/share
-
Dividend
-
Dividend %
-
Employees
98
Optionable
No
Shortable
Yes
Earnings
20 Jun 2024
P/E
-0.79
Forward P/E
-
PEG
-0.3
P/S
108.87
P/B
2.15
P/C
-
P/FCF
-1.04
Quick Ratio
3.14
Current Ratio
3.78
Debt / Equity
-
LT Debt / Equity
-
-
-
EPS (TTM)
-2.12
EPS next Y
-
EPS next Q
-
EPS this Y
10.71%
EPS next Y
-
EPS next 5Y
-
EPS last 5Y
19.29%
Revenue last 5Y
-100%
Revenue Q/Q
63.6%
EPS Q/Q
-1.96%
-
-
-
-
SMA20
-25%
SMA50
-25%
SMA100
-40%
Inst Own
-
Inst Trans
-
ROA
-121%
ROE
-187%
ROC
-1.34%
Gross Margin
-117%
Oper. Margin
-11909%
Profit Margin
-13727%
Payout
-
Shs Outstand
-
Shs Float
-
-
-
-
-
Target Price
-
52W Range
1.17-6.4
52W High
-50.08%
52W Low
+199.5%
RSI
40
Rel Volume
0.34
Avg Volume
301.42K
Volume
103.06K
Perf Week
-11.91%
Perf Month
-47.46%
Perf Quarter
-62.56%
Perf Half Y
-62.56%
-
-
-
-
Beta
-0.187
-
-
Volatility
0.16%, 0.39%
Prev Close
1.18%
Price
2.995
Change
-5.82%

Something similar

Top by Market Cap
3V64.DE
M&M.NS
NVDA
TL0.DE
MIX.JO
Same Sector
SWTX
GENN
MASS
MVIR-B.ST
LYS.PA
Top Correlated Stocks
GBR
BRN
EVGN
VIVC
CNQ
Similar Market Cap
HVBC
002781.SZ
INVE
V20D.DE
DAX

Company Profile

Healthcare Medical - Devices
  • Volume Average 301.42K
  • Market Capitalization 66.1M
  • Employee 98
  • CEO Mr. Steven Adam Lisi
  • Headquarters Garden City,NY,US
  • IPO Date 2018-06-12
  • Website https://www.beyondair.net

Beyond Air, Inc. operates as a commercial medical device and biopharmaceutical company. The company engages in the development of LungFit platform, a nitric oxide generator and delivery system. It offers LungFit PH for the treatment of persistent pulmonary hypertension of the newborn. The company is also developing LungFit PRO for the treatment of viral lung infections, such as community-acquired viral pneumonia, including COVID-19, as well as bronchiolitis in hospitalized patients; and LungFit GO for the treatment of nontuberculous mycobacteria. The company was formerly known as AIT Therapeutics, Inc. and changed its name to Beyond Air, Inc. in June 2019. Beyond Air, Inc. is based in Garden City, New York.